# ImmunoBiology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immunobiology

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.immbio.com
- Total disclosed funding: $9.5M
- Latest round: Series C (Jan 23, 2006)
- Investors on record: 5

## About

ImmunoBiology is a biotechnology firm focused on developing innovative immunotherapies and diagnostic solutions to enhance health outcomes in various medical fields.Founded in 1999 in Cambridge, UK, ImmunoBiology specializes in immunotherapy and diagnostics. The company has undergone strategic pivots to address emerging healthcare needs. It has secured GBP 3 million in funding from investors including Hygea VCT PLC and Rockridge Investments, valuing the company at GBP 4.45 million post-money as of August 2012. The CEO is Graham Clarke, whose prior entrepreneurial experience includes founding and managing other ventures, although no specific companies are mentioned.ImmunoBiology delivers advanced immunotherapies and diagnostic tools aimed at improving health outcomes. Its core offerings are designed to enhance patient care in medical fields such as oncology and infectious diseases. By catering to healthcare providers, the company aims to support better treatment decisions and patient management. Strategic market positioning in North America, Europe, and Asia allows ImmunoBiology to target a diverse customer base, including hospitals and research institutions.In the most recent financial year, ImmunoBiology reported zero revenue with an EBITDA of -746,696.4 GBP for the year 2020. The company relies on a revenue model that encompasses partnerships for software licenses and subscriptions, ensuring ongoing support and updates tailored to client needs. The tiered pricing plan facilitates access for various organizations, driving revenue through established client relationships and flagship products.ImmunoBiology plans to leverage the GBP 3 million raised in its latest funding round to support the development of new immunotherapy products and expand into emerging markets in Asia and Latin America by 2025. The company is focused on enhancing its product portfolio with innovative solutions that meet the evolving demands of the healthcare sector. This funding will enable further research and development initiatives, aimed at solidifying the company's presence in these strategic growth areas.

## Funding rounds

- Series C, Jan 23, 2006, $9.5M — Avlar BioVentures, Inventages Venture Capital, Oxford Technology Management, YFM Equity Partners, Generics Asset Management

## Investors

- Avlar BioVentures (https://capitalatlas.ai/funds/avlar-bioventures) — Series C
- Inventages Venture Capital (https://capitalatlas.ai/funds/inventages-venture-capital) — Series C
- Oxford Technology Management (https://capitalatlas.ai/funds/oxford-technology-management) — Series C
- YFM Equity Partners (https://capitalatlas.ai/funds/yfm-equity-partners) — Series C
- Generics Asset Management — Series C